DDInter228 DDInter1147
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitavastatin
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Brentuximab vedotin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Brentuximab vedotin {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide
Brentuximab vedotin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam